欧诺宁通过准卡斯巴酶3和CD274表达水平来缓解甲状腺癌的进展
Liangliang Du1, Douyun Zeng1, Xian Hu1
1Department of Endocrinology, Yueyang Hospital of Traditional Chinese Medicine.
Biological & pharmaceutical bulletin
|August 2, 2023
概括
一种天然化合物欧诺宁抑制甲状腺癌 (TC) 细胞生长,并促进细胞亡. 它调节酶3 (CASP3) 和CD274的表达,为甲状腺癌提供了潜在的治疗策略.
科学领域:
- 内分泌学 在内分泌学.
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 甲状腺癌 (TC) 是最常见的内分泌恶性瘤.
- 欧诺宁是一种异黄,具有抗氧化和抗炎性质.
- 了解欧诺宁在TC进展中的作用对于开发新疗法至关重要.
研究的目的:
- 为了研究欧诺宁对甲状腺癌细胞的抗癌作用.
- 阐明奥诺宁在TC中作用的分子机制.
主要方法:
- 使用细胞计数套件-8 (CCK8) 试验评估了细胞活力.
- 细胞亡和细胞死亡通过TUNEL染色和流动细胞计分析.
- 确定CASP3和CD274的基因和蛋白质表达水平,使用qRT-PCR和西方涂抹.
主要成果:
- 奥诺宁显著降低了TC细胞活力,并诱导了细胞亡.
- 在TC细胞中,欧诺宁治疗降低了CD274表达,增加了CASP3表达.
- 奥诺宁增强了T细胞细胞毒性,其效应被CASP3过度表达或CD274敲击强化.
结论:
- 欧诺宁通过抑制细胞增殖和诱导亡,表现出抗甲状腺癌的活性.
- 欧诺宁通过调节CASP3和CD274表达来发挥其作用.
- 奥诺宁代表了甲状腺癌治疗的有前途的治疗候选者.
相关概念视频
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
NF-κB-dependent Signaling Pathway
7.5K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.5K
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
The Intrinsic Apoptotic Pathway
6.6K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.6K
Cancer Therapies
7.7K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K


